Humacyte, Inc.
HUMA
$1.47
-$0.03-2.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -6.46% | -26.80% | 2.36% | 23.58% | 15.64% |
| Gross Profit | 7.73% | 29.23% | -2.36% | -23.58% | -15.64% |
| SG&A Expenses | 35.90% | 53.11% | 23.83% | 20.38% | 86.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.79% | -10.82% | 7.28% | 22.79% | 24.87% |
| Operating Income | -0.77% | 12.77% | -7.28% | -22.79% | -24.87% |
| Income Before Tax | 33.54% | 222.71% | 16.59% | -50.81% | -149.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.54% | 222.71% | 16.59% | -50.81% | -149.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.54% | 222.71% | 16.59% | -50.81% | -149.55% |
| EBIT | -0.77% | 12.77% | -7.28% | -22.79% | -24.87% |
| EBITDA | -0.53% | 13.86% | -7.93% | -24.70% | -28.09% |
| EPS Basic | 49.04% | 200.71% | 31.94% | -30.64% | -116.43% |
| Normalized Basic EPS | 20.66% | 68.08% | 19.12% | -7.13% | -12.79% |
| EPS Diluted | 49.52% | 199.66% | 31.94% | -30.64% | -118.48% |
| Normalized Diluted EPS | 20.66% | 68.15% | 19.12% | -7.13% | -12.79% |
| Average Basic Shares Outstanding | 30.43% | 21.60% | 22.56% | 15.43% | 15.30% |
| Average Diluted Shares Outstanding | 30.43% | 21.84% | 22.56% | 15.43% | 15.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |